Drug firm Suven Life Sciences Ltd. has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases or an ailment which primarily affects the brain.
In a BSE filing today, Suven Life said it has been granted "One product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro-degenerative diseases."
The patents are valid through 2030 and 2029 respectively, the company added.
We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.Venkat Jasti, CEO, Suven Life Sciences
With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel.
These patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II.Suven Life Sciences' Regulatory Filing
Suven Life Sciences shares were trading 2.32 percent up at Rs 198.65 on BSE in the morning trade.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories ā On NDTV Profit.
